No abstract available
Keywords:
CSAI; Parkinson's disease; apomorphine; continuous subcutaneous infusion; thrombocytopenia.
PubMed Disclaimer
References
-
-
Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's disease: efficacy and safety of current and new formulations. CNS Drugs 2019;33(9):905–918. 10.1007/s40263-019-00661-z.
-
DOI
-
PMC
-
PubMed
-
-
Pot C, Oppliger R, Castillo V, Coeytaux A, Hauser C, Burkhard PR. Apomorphine‐induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease. Neurology 2005;64(2):392–393. 10.1212/01.WNL.0000149757.47854.6F.
-
DOI
-
PubMed
-
-
Venegas Pérez B, Arquero Portero T, Sánchez Fernández MS, Feliz Feliz C, del Val FJ, García‐Ruiz PJ. Apomorphine‐induced immune hemolytic anemia. Mov Disord Clin Pract 2017;4(1):145–147. 10.1002/mdc3.12373.
-
DOI
-
PMC
-
PubMed
-
-
Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug‐induced immune thrombocytopenia. J Clin Med 2020;9(7):1–19. 10.3390/jcm9072212.
-
DOI
-
PMC
-
PubMed